MedTrace Logo

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-02-24

Study results available
· View outcomes & findings →

Summary

Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)

Conditions

Interventions

DRUG

Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]

antiviral therapy for HCV

DRUG

Sofosbuvir/Velpatasvir (SOF/VEL)

antiviral therapy for HCV

Sponsors & Collaborators

Principal Investigators

  • Mark Sulkowski, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02938013 on ClinicalTrials.gov